| Irit Arbel |
Dr. Irit Arbel is a Chief Executive Officer & Director at Neurocords Corp., a Vice Chairman at Brainstorm Cell Therapeutics, Inc., a Member at American Neurological Association and a Member at American Society of Hematology. She is on the Board of Directors at Neurocords Corp. and Brainstorm Cell Therapeutics, Inc. Dr. Arbel was previously employed as an Independent Director by Isracann Biosciences, Inc., an Executive Vice President-Research & Development by Online Disruptive Technologies, Inc., an Executive Vice President-Research & Development by Savicell Diagnostic Ltd., a Chief Executive Officer by ATC Systems, Inc., a Chairman by BRH Medical Ltd., a Chairman by Real Aesthetics Ltd., a President & Chief Executive Officer by Pluristem Therapeutics, Inc., a Head-Investor Relations by Global Energy, Inc., a Sales Manager by Merck Sharp & Dohme Corp., and a Director-Mergers & Acquisitions by RFB Investment House. She received her undergraduate degree from Technion-Israel Institute of Technology. |
| Stacy R. Lindborg |
Stacy R. Lindborg is currently an Independent Director at Imunon, Inc., a Director at Brainstorm Cell Therapeutics, Inc., a Director at Slone Career Strategies, Inc., and a Director at Massachusetts Down Syndrome Congress. Previously, she worked at Eli Lilly & Co. as the Head of Research & Development Strategy from 1996 to 2012, and at Biogen, Inc. as the Vice President of Analytics & Data Science from 2018 to 2020. Dr. Lindborg obtained her undergraduate, graduate, and doctorate degrees from Baylor University in 1992, 1993, and 1996 respectively. |
| Sidney A. Spector |
Presently, Sidney A. Spector is Senior VP-Global Strategy & Medical Affairs at Brainstorm Cell Therapeutics, Inc. Dr. Spector is also Associate Professor at the University of Arizona College of Medicine and Chief Medical Officer at Proxenia Venture Partners LLC.
In his past career Dr. Spector occupied the position of Vice President-US Medical Affairs at Novartis Gene Therapies, Inc. and Vice President at AveXis EU Ltd.
Dr. Spector received a doctorate from the University of California, Los Angeles and a doctorate from Sackler School of Medicine. |
| Kim Thacker |
Presently, Kim Thacker is Senior VP-Medical Affairs & Clinical Innovation at Brainstorm Cell Therapeutics, Inc. He is also President for American Tap Dance Foundation.
In the past he occupied the position of Vice President-Medical Affairs for UroGen Pharma Ltd.
Dr. Thacker received a doctorate from State University of New York at Downstate Medical Center. |
| Bob Dagher |
Dr. Bob Dagher, MD, is a Chief Medical Officer & Executive Vice President at Brainstorm Cell Therapeutics, Inc. Dr. Dagher was previously employed as a Chief Medical Officer by Enveric Biosciences, Inc., a Chief Medical Officer-WCG MedAvante-ProPhase by Cadent Therapeutics, Inc., a Senior Medical Director by Covance, Inc., and a Chief Medical Officer by MedAvante-ProPhase, Inc. He received his undergraduate degree from Université de Bordeaux and an undergraduate degree from Faculté De Médecine Necker Enfants Malades Université. |
| Netta Blondheim-Shraga |
Netta Blondheim-Shraga is currently the Vice President-Research & Development at Brainstorm Cell Therapeutics, Inc. She previously worked as a Study Director at Crown Bioscience, Inc. from 2019 to 2020. Dr. Blondheim-Shraga has a graduate degree from Tel-Aviv University, an undergraduate degree from The Hebrew University of Jerusalem, and a doctorate from Bar-Ilan University and the Faculty of Medicine. |
| Antal Pearl-Lendner |
Antal Pearl-Lendner is currently the Chief Legal Counsel & Vice President at Brainstorm Cell Therapeutics, Inc. She graduated from Tel-Aviv University with a graduate degree and earned an MBA from MIT Sloan School of Management. |
| Jacob Aharon Frenkel |
Jacob Aharon Frenkel is currently the Chairman at Brainstorm Cell Therapeutics, Inc., Plus500 Ltd., and The Group of Thirty. He also holds positions as the Director at The Frenkel-Zuckerman Institute for Global Economics, Peter G. Peterson Institute for International Economics, National Bureau of Economic Research, Inc., The Council for the United States & Italy, Aspen Institute Italia, The Japan Society, The Institute for National Security Studies, and Vivion Investments SARL. Additionally, he is a Member of The Trilateral Commission. In the past, Dr. Frenkel served as the Chief Executive Officer & Governor at Bank of Israel, Vice Chairman at American International Group, Inc., Vice Chairman-Governors Board at European Bank for Reconstruction & Development, Chairman at JPMorgan Chase & Co., Chairman-Governors Board at Inter-American Development Bank, Chairman at Merrill Lynch International, Inc., Chairman-Governors Board at Tel-Aviv University, Independent Director at Loews Corp., Independent Director at Boston Properties, Inc., Director at Boston Properties LP, Research Director at International Monetary Fund, and Professor at The University of Chicago. He was also a Trustee at The Economic Club of New York and an Advisor at Healthcare Capital Corp. (Delaware). Furthermore, he is a Member of the National Academy of Sciences and The G20 Eminent Persons Group on Global Financial Governance. Dr. Frenkel obtained his graduate and doctorate degrees from The University of Chicago and his undergraduate degree from The Hebrew University of Jerusalem. |
| Uri Yablonka |
Uri Yablonka is currently the Secretary, Director, Chief Business Officer & EVP at Brainstorm Cell Therapeutics, Inc. Prior to this, he was the Vice President-Business Development at ACC International Holdings Ltd. from 2011 to 2014. He also served as the General Manager & Owner of Mr. Yablonka Ltd. Additionally, he worked as a Senior Partner at Pm Pr Media Consulting Ltd. from 2008 to 2011. |
| Yael Gothelf |
Yael Gothelf is currently the Vice President of Scientific & Regulatory Affairs at Brainstorm Cell Therapeutics, Inc. since 2007. Prior to this, Yael worked as a Scientific Manager for Research & Process Development at Interpharm Laboratories Ltd. Yael holds a doctorate degree from Tel-Aviv University. |
| Alla Patlis |
Ms. Alla Patlis is a Chief Financial Officer & Controller at Brainstorm Cell Therapeutics, Inc. Ms. Patlis was previously employed as a Member by Deloitte Touche Tohmatsu Ltd. She received her undergraduate degree from Tel-Aviv University and an MBA from Tel-Aviv University. |
| Chaim Lebovits |
Chaim Lebovits is currently the President & Chief Executive Officer at Brainstorm Cell Therapeutics, Inc. since 2007. He is also the Director at Dominion Minerals Corp. since 2008 and the President at ACC Holdings International since 2007. Previously, he served as the Non-Executive Director at Calima Energy Ltd. from 2010 to 2012. |
| June Sherie Almenoff |
June Sherie Almenoff is Chief Medical Officer at RedHill Biopharma Ltd. She is also on the board of Tenax Therapeutics, Inc., Brainstorm Cell Therapeutics, Inc. and Avalo Therapeutics, Inc.
In the past she occupied the position of Chief Operating & Medical Officer at 9 Meters Biopharma, Inc. and Director at RDD Pharma Ltd. (a subsidiary of 9 Meters Biopharma, Inc.), President, CEO, Director & Chief Marketing Officer at Furiex Pharmaceuticals, Inc., Vice President-Clinical Safety Organization at GlaxoSmithKline LLC and Member of Infectious Diseases Society of America.
June Sherie Almenoff received an undergraduate degree from Smith College and a doctorate from Icahn School of Medicine at Mount Sinai. |
| Menghisteab Bairu |
Menghisteab Bairu is the founder of Proxenia Venture Partners LLC (founded in 2016) where he holds the title of Chairman and CEO. He is also the founder of Bio Usawa, Inc. (founded in 2023) where he serves as the President and Chief Executive Officer. Additionally, he is the founder of Serenus Biotherapeutics, Inc. (founded in 2013) and holds the title of Chairman-Emeritus. Dr. Bairu currently holds the position of Independent Director at Brainstorm Cell Therapeutics, Inc. since 2021 and is a Board Member at Himalayan Cataract Project since 2021. In his former roles, Dr. Bairu served as the President and Chief Executive Officer of Speranza Therapeutics, Inc. and Chairman and Chief Executive Officer of Bairex Medical. He was also the Executive Chairman of Treos Bio Ltd. from 2016 to 2019. Additionally, he held positions such as Director at Alzheon, Inc. and A-CUBE, Inc., Medical Director at Fremont Health Corp., and Chief Medical Officer and Head of Development at Elan Corp. Plc from 2013 to 2014. He was a Board Member at NewBridge Pharmaceuticals FZ LLC from 2013 to 2014 and served as the Executive Vice President of Prothena Therapeutics Ltd. from 2011 to 2013. Dr. Bairu obtained a doctorate degree from the University of Milan. |
| Anthony J. Polverino |
Dr. Anthony J. Polverino is an Independent Director at Brainstorm Cell Therapeutics, Inc. He is on the Board of Directors at Brainstorm Cell Therapeutics, Inc. Dr. Polverino was previously employed as a Chief Scientific Officer & EVP-Early Development by Zymeworks BC, Inc., a Chief Scientific Officer by Kite Pharma, Inc., and an Executive Director-Therapeutic Innovation Unit by Amgen, Inc. He received his undergraduate degree from the University of Adelaide and a doctorate degree from Flinders University. |
| Nir Naor |
Nir Naor is an Independent Director at Brainstorm Cell Therapeutics, Inc. and the Chief Financial Officer at Axogen, Inc. He previously worked as an Auditor at KPMG Corporate Finance LLC from 2001 to 2005. From 2012 to 2017, he served as the Chief Financial Officer-United States at UCB SA. He also held the position of Chief Financial Officer at Arbor Pharmaceuticals, Inc. in 2021 and Chief Financial Officer-US Americas at Molnlycke Health Care US LLC from 2017 to 2021. Additionally, he was the Chief Financial Officer at QuVa Pharma, Inc. in 2023 and Hmnc Brain Health GmbH from 2021 to 2022. Mr. Naor obtained his undergraduate and graduate degrees from Tel-Aviv University, and he holds an MBA from the International Institute for Management Development. |
